EGFR and skin neoplasm: The binding of prodigiosin to the active site of EGFR-TK indicated that the compound may be able to interfere with the receptor’s kinase activity, thereby inhibiting the downstream signaling cascades that promote uncontrolled cell division and tumor growth, and this result validated prodigiosin’s anticancer properties, especially against skin cancer cells.